Cargando…

Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial

BACKGROUNDS: the prevalence of infertility is up to 10 to 15 % which 9 to 24 % of them are Poor Ovarian Responders (POR). This study was designed to compare two methods of GnRH Agonist Microdose Flareup (MF) and GnRH Antagonist/Letrozole (AL) in treatment of these patients. METHODS AND MATERIALS: th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabati, Azar, Peivandi, Sepideh, Khalilian, Alireza, Mirzaeirad, Sina, Hashemi, Seyyed Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Center of Science and Education 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873585/
https://www.ncbi.nlm.nih.gov/pubmed/26573041
http://dx.doi.org/10.5539/gjhs.v8n4p166
_version_ 1782432906420944896
author Nabati, Azar
Peivandi, Sepideh
Khalilian, Alireza
Mirzaeirad, Sina
Hashemi, Seyyed Abbas
author_facet Nabati, Azar
Peivandi, Sepideh
Khalilian, Alireza
Mirzaeirad, Sina
Hashemi, Seyyed Abbas
author_sort Nabati, Azar
collection PubMed
description BACKGROUNDS: the prevalence of infertility is up to 10 to 15 % which 9 to 24 % of them are Poor Ovarian Responders (POR). This study was designed to compare two methods of GnRH Agonist Microdose Flareup (MF) and GnRH Antagonist/Letrozole (AL) in treatment of these patients. METHODS AND MATERIALS: this randomized clinical trial study consisted of 123 patients. In the first step of treatment in both methods FSH, LH, estradiol, anderostandion, testestron in third day of menstruation period and the thickness of endometrium by Transvaginal sonography were evaluated. At the time of HCG injection the thickness of endometrium and follicles which were more than 14mm ware established and hormones were evaluated. Two weeks later serum βhCG and after 6 to 8 weeks Transvaginal sonography were applied to prove the pregnancy. RESULTS: there were 61 patients with mean age of 38.7±4.58 in MF group and 62 patients with mean age of 38.5±4.6 in AL group (P=0.80). At the time of hCG injection there were significant increase in the level of LH, estradiol, thickness of endometrium and follicles more than 14mm in MF patients (P<0.0001). The mean time of ovary stimulation in MF group was 10.72±1.5 and in AL was 8.45±1.2 (P<0.0001). The mean level of gonadotropin which were used was 80.6±20.1 in MF patients and 64.7±16.4 in AL group (P<0.0001). 18 % of MF group and 38.7% in AL group had no normal cycle of ovulation (OR: 2.87, 95% CI: 1.25-6.57, P=0.011). The mean numbers of oocyte and normal fetus in MF was 5.83±3.5 and 3.7±2.5 and in AL was 3±1.69 and 1.4±1.33 (P<0.0001). The number of chemical pregnancy in MF group was 10 (16.4%) and in AL was 3 (4.8%) (OR 3.85, 95% CI: 1.06-14.77, P=0.037). Clinical pregnancy in 10 patients (16.4%) of MF group and 3 (4.8%)in AL was reported. OR 3.85, 95% CI: 1.06-14.77, P=0.037). CONCLUSION: this study showed that MF method of pregnancy leads to more positive results in pregnancy based on chemical and clinical evaluation in comparison with AL and is advised for poor responder patients.
format Online
Article
Text
id pubmed-4873585
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Canadian Center of Science and Education
record_format MEDLINE/PubMed
spelling pubmed-48735852016-05-26 Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial Nabati, Azar Peivandi, Sepideh Khalilian, Alireza Mirzaeirad, Sina Hashemi, Seyyed Abbas Glob J Health Sci Articles BACKGROUNDS: the prevalence of infertility is up to 10 to 15 % which 9 to 24 % of them are Poor Ovarian Responders (POR). This study was designed to compare two methods of GnRH Agonist Microdose Flareup (MF) and GnRH Antagonist/Letrozole (AL) in treatment of these patients. METHODS AND MATERIALS: this randomized clinical trial study consisted of 123 patients. In the first step of treatment in both methods FSH, LH, estradiol, anderostandion, testestron in third day of menstruation period and the thickness of endometrium by Transvaginal sonography were evaluated. At the time of HCG injection the thickness of endometrium and follicles which were more than 14mm ware established and hormones were evaluated. Two weeks later serum βhCG and after 6 to 8 weeks Transvaginal sonography were applied to prove the pregnancy. RESULTS: there were 61 patients with mean age of 38.7±4.58 in MF group and 62 patients with mean age of 38.5±4.6 in AL group (P=0.80). At the time of hCG injection there were significant increase in the level of LH, estradiol, thickness of endometrium and follicles more than 14mm in MF patients (P<0.0001). The mean time of ovary stimulation in MF group was 10.72±1.5 and in AL was 8.45±1.2 (P<0.0001). The mean level of gonadotropin which were used was 80.6±20.1 in MF patients and 64.7±16.4 in AL group (P<0.0001). 18 % of MF group and 38.7% in AL group had no normal cycle of ovulation (OR: 2.87, 95% CI: 1.25-6.57, P=0.011). The mean numbers of oocyte and normal fetus in MF was 5.83±3.5 and 3.7±2.5 and in AL was 3±1.69 and 1.4±1.33 (P<0.0001). The number of chemical pregnancy in MF group was 10 (16.4%) and in AL was 3 (4.8%) (OR 3.85, 95% CI: 1.06-14.77, P=0.037). Clinical pregnancy in 10 patients (16.4%) of MF group and 3 (4.8%)in AL was reported. OR 3.85, 95% CI: 1.06-14.77, P=0.037). CONCLUSION: this study showed that MF method of pregnancy leads to more positive results in pregnancy based on chemical and clinical evaluation in comparison with AL and is advised for poor responder patients. Canadian Center of Science and Education 2016-04 2015-08-06 /pmc/articles/PMC4873585/ /pubmed/26573041 http://dx.doi.org/10.5539/gjhs.v8n4p166 Text en Copyright: © Canadian Center of Science and Education http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Articles
Nabati, Azar
Peivandi, Sepideh
Khalilian, Alireza
Mirzaeirad, Sina
Hashemi, Seyyed Abbas
Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial
title Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial
title_full Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial
title_fullStr Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial
title_full_unstemmed Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial
title_short Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial
title_sort comparison of gnrh agonist microdose flare up and gnrh antagonist/letrozole in treatment of poor responder patients in intra cytoplaspic sperm injection: randomized clinical trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873585/
https://www.ncbi.nlm.nih.gov/pubmed/26573041
http://dx.doi.org/10.5539/gjhs.v8n4p166
work_keys_str_mv AT nabatiazar comparisonofgnrhagonistmicrodoseflareupandgnrhantagonistletrozoleintreatmentofpoorresponderpatientsinintracytoplaspicsperminjectionrandomizedclinicaltrial
AT peivandisepideh comparisonofgnrhagonistmicrodoseflareupandgnrhantagonistletrozoleintreatmentofpoorresponderpatientsinintracytoplaspicsperminjectionrandomizedclinicaltrial
AT khalilianalireza comparisonofgnrhagonistmicrodoseflareupandgnrhantagonistletrozoleintreatmentofpoorresponderpatientsinintracytoplaspicsperminjectionrandomizedclinicaltrial
AT mirzaeiradsina comparisonofgnrhagonistmicrodoseflareupandgnrhantagonistletrozoleintreatmentofpoorresponderpatientsinintracytoplaspicsperminjectionrandomizedclinicaltrial
AT hashemiseyyedabbas comparisonofgnrhagonistmicrodoseflareupandgnrhantagonistletrozoleintreatmentofpoorresponderpatientsinintracytoplaspicsperminjectionrandomizedclinicaltrial